# Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.

> **NCT00326118** · PHASE3 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 433 (actual)

## Conditions studied

- Haemophilus Influenzae Type b
- Neisseria Meningitidis

## Interventions

- **BIOLOGICAL:** Haemophilus influenzae type b and meningococcal serogroup C (vaccine)
- **BIOLOGICAL:** Priorix™
- **BIOLOGICAL:** Hiberix™
- **BIOLOGICAL:** Meningitec™

## Key facts

- **NCT ID:** NCT00326118
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06-01
- **Primary completion:** 2007-11-01
- **Final completion:** 2007-11-06
- **Target enrollment:** 433 (ACTUAL)
- **Last updated:** 2018-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00326118

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00326118, "Study in Toddlers to Demonstrate Non-inferiority of GSK Biologicals' Hib-MenC & to Evaluate Persistence up to 5 Years.". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00326118. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*